The Bioanalytical Laboratory Joins a Mere Three Percent of Companies to Make the List Six Times

AUGUST 14, 2019—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has been named to Inc. Magazine’s Inc. 5000 list of the fastest-growing private companies in America for 2019: its sixth appearance on the list in the last seven years. The annual list recognizes the most innovative and entrepreneurial businesses in the country, providing a ranking of private, for-profit, and independent companies that have achieved significant percentage growth of annual revenue over the three previous years. This year BioAgilytix came in among the top half of companies listed, ranking at #1968.

This latest appearance puts BioAgilytix in an exclusive class, as a mere three percent of companies have made the Inc. 5000 list six times. In addition to coming in at #1833 in 2018, BioAgilytix was also ranked in 2017, 2016, 2014, and 2013. BioAgilytix’s consistent and sustained high growth, particularly in a rapidly evolving space like the bioanalytical field, speaks both to the rising demand for large molecule bioanalysis to support an exploding biologics market, and to BioAgilytix’s commitment to strategically expanding its capacity, resources, and team to deliver premier immunogenicity, pharmacokinetic, cell-based assay, and biomarker services that accelerate development of innovative biologic drugs.

In fact, in the year since its 2018 listing, BioAgilytix has not only grown the capacity for all its bioanalytical services with a 21,173 square foot facility expansion at its USA headquarters, but was also acquired by Cobepa S.A., a privately-held investment company, late last year. The acquisition has provided BioAgilytix with further funding and resources to meet growing demand for its high-quality services, particularly in new programs like those involving gene and cell therapy and immuno-oncology.

“I am very proud to have our team recognized once again by Inc. 5000 on this prestigious list,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “We always say that the best science demands the best people, and our employees – and their commitment to delivering for our customers, every time – have enabled us to grow to where we are today. It’s because of them that we’re ranked top in our industry for quality and customer satisfaction, and why current and new customers turn to us to help get their life-changing products safely into the hands of patients. The fact that we supported 8 of the 18 large molecule drugs approved by the FDA last year is just another testament to our team’s expertise, dedication, and quality focus. The most exciting part is that this is just the beginning: the future is bright for BioAgilytix and our team.”

In addition to being profiled on Inc.com, all listed companies will also be honored at the Inc. 5000 Conference and Gala held October 10 through 12, 2019 in Phoenix, Arizona.

###

About BioAgilytix

BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.

Media Contact:
Jennifer Absher
BioAgilytix
(919) 287-1573
media@bioagilytix.com